PREventing CHemotherapy Induced Neuropathy (PreChIN)

National University Hospital, Singapore89 enrolled

Overview

The project is designed to study the use of localized hypothermia alone, or with compression to the limbs during chemotherapy infusion for the prevention of chemotherapy induced peripheral neuropathy (CIPN). As a pilot study, safety, tolerability and early clinical activity will be studied. The study will be conducted on healthy volunteers and cancer patients receiving taxane chemotherapy.

Localized limb hypothermia during chemotherapeutic infusion may prevent a common side effect of chemotherapy: chemotherapy-induced peripheral neuropathy (CIPN). There are no reliable methods for the prevention or the treatment of CIPN. On the basis of the dose-related pathophysiology of CIPN, the investigators hypothesize that reducing the delivery of the toxic chemotherapeutic agents to the peripheral nerves by reducing blood flow through hypothermia may reduce the occurrence of CIPN. The proposed potential treatment method would aim to reduce the development of CIPN. This project comprises of a healthy subject trial to investigate the best tolerated temperature which will be used in cancer subject trial to investigate the safety and tolerability of hypothermia or cryocompression (hypothermia with pressure) in the prevention of CIPN in cancer subjects undergoing taxane-based chemotherapy.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Chemotherapy-induced Peripheral Neuropathy (CIPN)

Interventions

HypothermiaDEVICE

Healthy subjects will undergo 3 hours of hypothermia at various temperature levels.Cancer subjects will undergo 4 hours of hypothermia during every cycle of chemotherapy.

CryocompressionDEVICE

Healthy subjects will undergo 3 hours of cryocompression. Cancer subjects will undergo a minimum duration of 2 hours and a maximum duration of up to 4 hours of cryocompression during every cycle of chemotherapy.

Eligibility

Sex: ALLMin age: 21 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

The inclusion criterion for the healthy subjects * Age 21-80 years * Signed informed consent from patient * No history of neuropathy * ECOG 0 * No history of hospitalization in the past 6 months The inclusion criteria for the cancer patients undergoing taxane-based chemotherapy * Age 21- 80 years. * Signed informed consent from patient or legal representative. * Scheduled to receive taxane-based chemotherapy The exclusion criteria for both healthy subjects and cancer patients * Open skin wound or ulcers of the limbs * A score of more than 5 in the Total Neuropathy Score (TNS) at baseline (Not applicable for healthy subjects) * History of Raynaud's phenomenon, peripheral vascular disease, or poorly controlled diabetes

Outcomes

Primary Outcomes

Number of healthy subjects with treatment-related intolerance as assessed by CTCAE v4.0 and tolerability scales undergoing limb hypothermia or cryocompression

Time frame: From the start of assessment until study completion, an average of 3 years

Number of cancer patients with treatment-related intolerance as assessed by CTCAE v4.0 and tolerability scales undergoing limb hypothermia or cryocompression

Time frame: From the start of assessment until study completion, an average of 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.